Staten Biotechnology LLC
23 Business Park Drive
Branford
Connecticut
06405-2904
United States
Tel: 203-208-2113
Website: http://www.statenbiotech.com/
Email: info@statenbiotech.com
About Staten Biotechnology LLC
Staten Biotechnology aims to develop novel and innovative strategies for the treatment of dyslipidemia, with a focus on the triglyceride space. Staten Biotechnology B.V. was incorporated in 2014 by world experts in dyslipidemia, Paul da Silva Jardine, Daniel Rader and Alan Tall. Daniela Couto is the Managing Director. Forbion Capital Partners and BioGeneration Ventures are its current investors.YEAR FOUNDED:
2014
LEADERSHIP:
Founders: Paul da Silva Jardine, Daniel Rader and Alan Tall
COO: Paul DaSilva-Jardine
Managing Director: Daniela Couto
5 articles about Staten Biotechnology LLC
-
Staten Biotechnology, in collaboration with Novo Nordisk, starts dosing of anti-apoC3 antibody SST-5058 in First-in-Human Trial
7/21/2020
Staten Biotechnology B.V. announced the initiation of dosing of the Company’s lead asset, STT-5058, in a First-in-Human clinical study.
-
Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia
12/17/2018
Forbion today announces that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia.
-
BioGeneration Ventures' portfolio company Staten Biotechnology announces collaboration with Novo Nordisk
12/17/2018
BioGeneration Ventures is pleased to announce that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement.
-
Dirk Kersten Joins Forbion as General Partner
6/14/2018
Forbion today announces that Dirk Kersten will join as a General Partner on October 1st, 2018.
-
Staten Biotech Exercises Option To Develop Therapeutic SIMPLE Antibody For Dyslipidemia From Argenx
3/6/2017